...
首页> 外文期刊>Pakistan journal of medical sciences. >ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy
【24h】

ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy

机译:ERCC1,RRM1和TUBB3 mRNA表达对铂类化学疗法治疗非小细胞肺癌的肿瘤反应和总体生存的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: We aimed to analyze the expression of ERCC1, RRM1 and TUBB3 in 305 patients with advanced non-small cell lung cancer (NSCLC) and investigate whether these genes can be used as biomarkers for predicting tumor response and clinical outcome.Methods: Total 305 patients with unresectable and locally advanced NSCLC were collected between January 2007 and December 2008. cDNA of ERCC1, RRM1 and TUBB3 was isolated by a fluorescence-based real-time detection method.Results: All the patients were followed up until December 2012. One hundred seventy five patients showed good response and 130 patients showed poor response to chemotherapy. 126 patients died and 166 patients showed progressive disease during the follow-up period. The median levels of ERCC1, RRM1 and TUBB3 mRNA were 0.53±0.13, 0.31±0.15 and 0.18±0.16, respectively. We found that patients with low ERCC1 expression showed a significantly higher rate of good tumor response, and the adjusted OR (95% CI) was 2.16(1.32-3.45). By Cox regression analysis. We also found that low ERCC1 expression level were correlated with longer overall survival of NSCLC patients, with the adjusted HR (95% CI) was 2.15 (1.26–3.35).Conclusion: This study showed that ERCC1 mRNA expression can not affect the response to chemotherapy and clinical outcome of advanced non-small cell lung cancer (NSCLC) patients.doi: http://dx.doi.org/10.12669/pjms.306.5768How to cite this:Qiao H, Huang X, Guo H, Liu Y, Yue C. ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy. Pak J Med Sci 2014;30(6):1403-1408. doi: http://dx.doi.org/10.12669/pjms.306.5768This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
机译:目的:我们分析305例晚期非小细胞肺癌(NSCLC)患者中ERCC1,RRM1和TUBB3的表达,并探讨这些基因是否可以用作预测肿瘤反应和临床结果的生物标志物。方法:共305篇于2007年1月至2008年12月收集了不可切除的局部晚期NSCLC患者。通过基于荧光的实时检测方法分离了ERCC1,RRM1和TUBB3的cDNA。结果:所有患者均获随访,直至2012年12月。一百例75例患者对化疗的反应良好,130例患者对化疗的反应较差。在随访期间有126例患者死亡,166例患者显示疾病进展。 ERCC1,RRM1和TUBB3 mRNA的中位水平分别为0.53±0.13、0.31±0.15和0.18±0.16。我们发现ERCC1表达低的患者表现出较高的良好肿瘤反应率,调整后的OR(95%CI)为2.16(1.32-3.45)。通过Cox回归分析。我们还发现ERCC1的低表达与NSCLC患者的总生存期较长有关,校正后的HR(95%CI)为2.15(1.26-3.35)。结论:这项研究表明ERCC1 mRNA的表达不能影响对HCC的反应。晚期非小细胞肺癌(NSCLC)患者的化疗和临床结局.doi:http://dx.doi.org/10.12669/pjms.306.5768如何引用此信息:乔H,黄X,郭H,刘瑜,岳C. ERCC1,RRM1和TUBB3 mRNA表达对铂类化学疗法治疗的非小细胞肺癌的肿瘤应答和总体生存率的影响。 Pak J Med Sci 2014; 30(6):1403-1408。 doi:http://dx.doi.org/10.12669/pjms.306.5768,这是根据知识共享署名许可(http://creativecommons.org/licenses/by/3.0)的条款分发的开放获取文章。只要适当引用了原始作品,便可以在任何介质中不受限制地使用,分发和复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号